CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: MRPL30 (ImmuneEditome ID:51263)

1. Gene summary of enriched editing regions for MRPL30

check button Gene summary
Gene informationGene symbol

MRPL30

Gene ID

51263

GeneSynonymsL28MT|L30MT|MRP-L28|MRP-L30|MRPL28|MRPL28M|RPML28
GeneCytomap

2q11.2

GeneTypeprotein-coding
GeneDescription39S ribosomal protein L30, mitochondrial|39S ribosomal protein L28, mitochondrial|mitochondrial large ribosomal subunit protein uL30m
GeneModificationdate20230329
UniprotIDQ8TCC3;B8ZZV5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:99195777-99196617:+ENST00000465432.1ENSG00000185414.18MRPL30ncRNA_exonicAluSx,AluJbchr2:99195777-99196617:+.alignment
chr2:99197623-99197965:+ENST00000338148.6ENSG00000185414.18MRPL30UTR3AluJr4chr2:99197623-99197965:+.alignment


Top

2. Tumor-specific enriched editing regions for MRPL30


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr2:99195777-99196617:+BRCAEER1.1305e-03image
ENSG00000185414.18,MRPL30BRCAEAG1.0909e-03image
chr2:99195777-99196617:+COADEER4.9878e-02image
ENSG00000185414.18,MRPL30COADEAG4.9878e-02image
chr2:99195777-99196617:+HNSCEER1.6646e-02image
ENSG00000185414.18,MRPL30HNSCEAG1.6646e-02image
chr2:99195777-99196617:+KICHEER3.7884e-08image
ENSG00000185414.18,MRPL30KICHEAG3.7884e-08image
chr2:99195777-99196617:+KIRCEER2.9879e-05image
chr2:99197623-99197965:+KIRCEER1.8186e-02image
ENSG00000185414.18,MRPL30KIRCEAG2.9879e-05image
chr2:99195777-99196617:+KIRPEER1.5250e-10image
chr2:99197623-99197965:+KIRPEER2.5122e-02image
ENSG00000185414.18,MRPL30KIRPEAG1.5250e-10image
chr2:99195777-99196617:+LUADEER3.8375e-04image
ENSG00000185414.18,MRPL30LUADEAG3.9004e-04image
chr2:99195777-99196617:+PRADEER3.2795e-04image
ENSG00000185414.18,MRPL30PRADEAG3.2795e-04image
chr2:99195777-99196617:+STADEER3.8664e-02image
ENSG00000185414.18,MRPL30STADEAG3.8664e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000185414.18,MRPL30KIRCPathEAG2.1381e-032.4995e-040.1596image
chr2:99195777-99196617:+KIRCPathEER2.1381e-032.4995e-040.1596image
chr2:99197623-99197965:+LUSCPathEER3.5492e-043.8215e-030.1876image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for MRPL30


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:99195777-99196617:+COADEERENSG00000201662,RNU6-60P0.13754.2240e-031.4671e-140.4446imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:99195777-99196617:+COADEERENSG00000233559,AC016831.70.22328.4056e-038.3028e-130.4167imageNEIF4A3;ELAVL1;HNRNPC;HNRNPK;PCBP2;PTBP1;TAF15;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_P53_PATHWAY
chr2:99195777-99196617:+COADEERENSG00000263526,MIR378G0.16112.4693e-027.8032e-150.4488imageNNNANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:99195777-99196617:+COADEERENSG00000238778,RNU7-80P0.10252.5157e-022.2346e-150.4568imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:99195777-99196617:+COADEERENSG00000212461,SNORA170.12322.7147e-026.3572e-130.4186imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:99195777-99196617:+COADEERENSG00000277075,HIST1H2AE0.18883.0971e-025.3425e-130.4199imageNEIF4A3;HNRNPC;HNRNPK;MOV10;PCBP2;PTBP1;TAF15;TARDBP;TROVE2;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr2:99195777-99196617:+COADEERENSG00000273802,HIST1H2BG0.18223.4674e-024.4828e-120.4042imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr2:99195777-99196617:+COADEERENSG00000253042,SNORA700.09954.5484e-021.4816e-120.4125imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:99195777-99196617:+HNSCEERENSG00000186010,NDUFA130.21802.9485e-053.8439e-230.4255imageNEIF4A3;ELAVL1;HNRNPC;HNRNPK;MOV10;PCBP2;PTBP1;TAF15;TARDBP;TROVE2;U2AF2NDUFA13T_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr2:99195777-99196617:+HNSCEERENSG00000235065,RPL24P20.20995.1412e-051.9387e-320.4988imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN

More results



Top

4. Enriched editing regions and immune related splicing for MRPL30


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:99195777-99196617:+
COADEERIRENSG00000100100.8chr2231291179:31291296:31292274:312923950.20804.2066e-022.9235e-110.4053imageNEIF4A3;ELAVL1;TAF15;TARDBP;TROVE2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr2:99195777-99196617:+
COADEERIRENSG00000149499.7chr1162608735:62609132:62609353:626094770.21444.2354e-022.0409e-120.4122imageNEIF4A3;ELAVL1;ELAVL3;HNRNPC;HNRNPK;MOV10;PCBP2;PTBP1;TAF15;TARDBP;TROVE2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000185414.18,MRPL30
COADEAGIRENSG00000108846.11chr1750676277:50678219:50679797:506798990.26434.9676e-036.8517e-130.4195imageNACIN1;AUH;BUD13;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;LIN28B;MSI1;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:99195777-99196617:+
COADEERIRENSG00000143375.10chr1151533974:151535131:151535599:1515356830.21164.8001e-023.1899e-120.4068imageNEIF4A3;ELAVL1;HNRNPC;HNRNPK;MOV10;PCBP2;TAF15;TARDBP;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000185414.18,MRPL30
COADEAGIRENSG00000100100.8chr2231291179:31291296:31292274:312923950.20804.7196e-022.9235e-110.4053imageNBUD13;CSTF2T;DDX42;DDX54;DICER1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28B;NOP56;NOP58;PRPF8;SF3B4;SLBP;SMNDC1;SND1;SRSF1;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr2:99195777-99196617:+
COADEERIRENSG00000108846.11chr1750676277:50678219:50679797:506798990.26434.1239e-036.8517e-130.4195imageNEIF4A3;ELAVL1;HNRNPC;HNRNPK;PCBP2;PTBP1;TAF15;TROVE2;U2AF2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000185414.18,MRPL30
COADEAGIRENSG00000149499.7chr1162608735:62609132:62609353:626094770.21444.7492e-022.0409e-120.4122imageNACIN1;AIFM1;ALYREF;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000185414.18,MRPL30
DLBCEAGIRENSG00000254870.1chr631531295:31532911:31535366:31535485-0.71163.0322e-022.2470e-03-0.4394imageNACIN1;AIFM1;ALYREF;AUH;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000185414.18,MRPL30
DLBCEAGIRENSG00000100242.11chr2238737759:38741571:38742300:387424380.73583.0322e-021.6036e-050.5954imageNACIN1;AIFM1;AUH;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAGSVA_HALLMARK_HEME_METABOLISM
ENSG00000185414.18,MRPL30
DLBCEAGMEXENSG00000110442.7chr1136274472:36274772:36276136:36276240:36280711:36280837:36289361:362894240.73623.1575e-021.4066e-070.6863imageNBUD13;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184NAMacrophages_M1GSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for MRPL30


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr2:99195777-99196617:+ACCEERT_cells_gamma_delta1.6601e-030.3548image
ENSG00000185414.18,MRPL30ACCEAGT_cells_gamma_delta1.6601e-030.3548image
chr2:99195777-99196617:+BLCAEERDendritic_cells_resting3.1972e-040.1786image
chr2:99197623-99197965:+BLCAEERT_cells_regulatory_(Tregs)3.4530e-02-0.2149image
ENSG00000185414.18,MRPL30BLCAEAGDendritic_cells_resting3.1972e-040.1786image
chr2:99195777-99196617:+BRCAEERT_cells_CD4_memory_resting1.6648e-03-0.0956image
ENSG00000185414.18,MRPL30BRCAEAGT_cells_CD4_memory_resting2.8595e-03-0.0907image
chr2:99195777-99196617:+CESCEERMacrophages_M11.3014e-02-0.1425image
ENSG00000185414.18,MRPL30CESCEAGMacrophages_M11.3014e-02-0.1425image
chr2:99195777-99196617:+CHOLEERT_cells_CD4_naive8.3685e-030.4388image
ENSG00000185414.18,MRPL30CHOLEAGT_cells_CD4_naive8.3685e-030.4388image
chr2:99195777-99196617:+COADEERT_cells_regulatory_(Tregs)5.7009e-04-0.2080image
chr2:99197623-99197965:+COADEERNeutrophils8.7795e-030.2316image
ENSG00000185414.18,MRPL30COADEAGT_cells_regulatory_(Tregs)5.7009e-04-0.2080image
chr2:99195777-99196617:+ESCAEERT_cells_CD87.8583e-050.3061image
chr2:99197623-99197965:+ESCAEERT_cells_CD4_memory_resting4.9108e-02-0.1620image
ENSG00000185414.18,MRPL30ESCAEAGT_cells_CD87.8654e-050.3061image
chr2:99197623-99197965:+GBMEERT_cells_follicular_helper2.4570e-02-0.2193image
chr2:99195777-99196617:+HNSCEERT_cells_CD4_memory_resting2.0405e-02-0.1043image
ENSG00000185414.18,MRPL30HNSCEAGT_cells_CD4_memory_resting2.0405e-02-0.1043image
chr2:99195777-99196617:+KIRCEERPlasma_cells4.0964e-040.1804image
chr2:99197623-99197965:+KIRCEERT_cells_regulatory_(Tregs)1.1911e-030.2063image
ENSG00000185414.18,MRPL30KIRCEAGPlasma_cells4.0964e-040.1804image
chr2:99197623-99197965:+KIRPEERT_cells_CD4_naive1.2477e-020.2354image
chr2:99195777-99196617:+LAMLEERB_cells_naive3.4619e-020.1738image
ENSG00000185414.18,MRPL30LAMLEAGB_cells_naive3.4619e-020.1738image
chr2:99195777-99196617:+LGGEERB_cells_naive3.6466e-040.1546image
ENSG00000185414.18,MRPL30LGGEAGB_cells_naive3.6466e-040.1546image
chr2:99195777-99196617:+LIHCEERMacrophages_M02.5062e-02-0.1198image
chr2:99197623-99197965:+LIHCEERT_cells_CD4_naive1.1860e-020.2262image
ENSG00000185414.18,MRPL30LIHCEAGMacrophages_M02.5062e-02-0.1198image
chr2:99195777-99196617:+LUADEEREosinophils6.0369e-03-0.1217image
chr2:99197623-99197965:+LUADEERDendritic_cells_resting8.5730e-030.1943image
ENSG00000185414.18,MRPL30LUADEAGEosinophils1.0789e-02-0.1130image
chr2:99195777-99196617:+LUSCEERB_cells_memory9.5178e-030.1161image
chr2:99197623-99197965:+LUSCEERB_cells_memory5.2420e-030.1812image
ENSG00000185414.18,MRPL30LUSCEAGB_cells_memory9.5178e-030.1161image
chr2:99195777-99196617:+MESOEERDendritic_cells_activated9.9102e-050.4214image
ENSG00000185414.18,MRPL30MESOEAGDendritic_cells_activated9.9102e-050.4214image
chr2:99195777-99196617:+OVEERT_cells_CD89.7502e-050.2260image
ENSG00000185414.18,MRPL30OVEAGT_cells_CD89.7534e-050.2260image
chr2:99195777-99196617:+PAADEERB_cells_memory1.4269e-020.1839image
ENSG00000185414.18,MRPL30PAADEAGB_cells_memory1.4269e-020.1839image
chr2:99197623-99197965:+PCPGEERT_cells_CD4_memory_activated3.7218e-020.2631image
chr2:99195777-99196617:+PRADEERB_cells_naive1.0488e-04-0.1733image
chr2:99197623-99197965:+PRADEERDendritic_cells_resting2.9946e-02-0.1506image
ENSG00000185414.18,MRPL30PRADEAGB_cells_naive1.0488e-04-0.1733image
chr2:99195777-99196617:+READEERT_cells_CD4_naive4.3015e-020.2081image
ENSG00000185414.18,MRPL30READEAGT_cells_CD4_naive4.3015e-020.2081image
chr2:99195777-99196617:+SARCEERT_cells_CD4_memory_activated1.1930e-020.1579image
chr2:99197623-99197965:+SARCEERMacrophages_M21.8243e-020.3627image
ENSG00000185414.18,MRPL30SARCEAGT_cells_CD4_memory_activated1.1930e-020.1579image
chr2:99195777-99196617:+SKCMEERMast_cells_activated2.6557e-020.1028image
chr2:99197623-99197965:+SKCMEERT_cells_CD4_naive1.1732e-020.1608image
ENSG00000185414.18,MRPL30SKCMEAGMast_cells_activated2.6557e-020.1028image
chr2:99195777-99196617:+STADEERT_cells_CD4_memory_activated2.9372e-030.1548image
ENSG00000185414.18,MRPL30STADEAGT_cells_CD4_memory_activated2.9372e-030.1548image
chr2:99197623-99197965:+TGCTEERMast_cells_resting3.2798e-02-0.2883image
chr2:99195777-99196617:+THCAEERT_cells_CD87.6087e-030.1195image
chr2:99197623-99197965:+THCAEERT_cells_regulatory_(Tregs)6.7402e-030.2030image
ENSG00000185414.18,MRPL30THCAEAGT_cells_CD87.6087e-030.1195image
chr2:99195777-99196617:+THYMEERT_cells_regulatory_(Tregs)1.3407e-030.2943image
ENSG00000185414.18,MRPL30THYMEAGT_cells_regulatory_(Tregs)1.3407e-030.2943image
chr2:99195777-99196617:+UCECEERT_cells_gamma_delta8.8650e-030.2014image
ENSG00000185414.18,MRPL30UCECEAGT_cells_gamma_delta8.8650e-030.2014image


Top

6. Enriched editing regions and immune gene sets for MRPL30


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr2:99195777-99196617:+ACCEER9.6753e-05-0.43221.2459e-02-0.28541.0765e-03-0.36794.0991e-03-0.3256image
ENSG00000185414.18,MRPL30ACCEAG9.6753e-05-0.43221.2459e-02-0.28541.0765e-03-0.36794.0991e-03-0.3256image
ENSG00000185414.18,MRPL30HNSCEAG2.4936e-02-0.10092.5145e-03-0.13575.9861e-03-0.12351.1885e-02-0.1131image
chr2:99195777-99196617:+HNSCEER2.4936e-02-0.10092.5145e-03-0.13575.9861e-03-0.12351.1885e-02-0.1131image
ENSG00000185414.18,MRPL30KIRCEAG8.2853e-06-0.22647.6128e-04-0.17206.4629e-06-0.22912.1228e-04-0.1889image
chr2:99195777-99196617:+KIRCEER8.2853e-06-0.22647.6128e-04-0.17206.4629e-06-0.22912.1228e-04-0.1889image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000185414.18,MRPL30ACCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.0517e-04-0.4032image
chr2:99195777-99196617:+ACCGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.0517e-04-0.4032image
chr2:99195777-99196617:+BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEER8.5163e-05-0.1947image
chr2:99197623-99197965:+BLCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.1113e-030.2972image
ENSG00000185414.18,MRPL30BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.5163e-05-0.1947image
ENSG00000185414.18,MRPL30BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.8273e-09-0.1734image
chr2:99195777-99196617:+BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0144e-08-0.1733image
chr2:99195777-99196617:+CESCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER4.1109e-03-0.1644image
ENSG00000185414.18,MRPL30CESCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG4.1109e-03-0.1644image
ENSG00000185414.18,MRPL30CHOLGSVA_HALLMARK_UV_RESPONSE_UPEAG3.8565e-03-0.4759image
chr2:99195777-99196617:+CHOLGSVA_HALLMARK_UV_RESPONSE_UPEER3.8565e-03-0.4759image
chr2:99195777-99196617:+COADGSVA_HALLMARK_ADIPOGENESISEER2.0540e-05-0.2556image
ENSG00000185414.18,MRPL30COADGSVA_HALLMARK_ADIPOGENESISEAG2.0540e-05-0.2556image
chr2:99195777-99196617:+DLBCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.3945e-04-0.5163image
ENSG00000185414.18,MRPL30DLBCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG2.3945e-04-0.5163image
chr2:99195777-99196617:+ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.5048e-080.4123image
chr2:99197623-99197965:+ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER5.4594e-030.2273image
ENSG00000185414.18,MRPL30ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.5148e-080.4123image
chr2:99195777-99196617:+GBMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.5455e-020.1729image
chr2:99197623-99197965:+GBMGSVA_HALLMARK_KRAS_SIGNALING_UPEER8.7435e-030.2547image
ENSG00000185414.18,MRPL30GBMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.5455e-020.1729image
chr2:99197623-99197965:+HNSCGSVA_HALLMARK_P53_PATHWAYEER1.9456e-050.3007image
chr2:99195777-99196617:+HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEER6.3677e-06-0.2015image
ENSG00000185414.18,MRPL30HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.3677e-06-0.2015image
ENSG00000185414.18,MRPL30KIRCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.7357e-09-0.2990image
chr2:99197623-99197965:+KIRCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.8506e-05-0.2645image
chr2:99195777-99196617:+KIRCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.7357e-09-0.2990image
chr2:99195777-99196617:+KIRPGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.0765e-06-0.2866image
chr2:99197623-99197965:+KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER1.3040e-04-0.3537image
ENSG00000185414.18,MRPL30KIRPGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.0765e-06-0.2866image
chr2:99195777-99196617:+LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEER5.9782e-04-0.2789image
ENSG00000185414.18,MRPL30LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.9782e-04-0.2789image
ENSG00000185414.18,MRPL30LGGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG3.4486e-06-0.2004image
chr2:99195777-99196617:+LGGGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.4486e-06-0.2004image
chr2:99197623-99197965:+LGGGSVA_HALLMARK_MYOGENESISEER7.7296e-080.2634image
chr2:99197623-99197965:+LIHCGSVA_HALLMARK_PROTEIN_SECRETIONEER4.6047e-03-0.2539image
ENSG00000185414.18,MRPL30LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.5718e-12-0.3626image
chr2:99195777-99196617:+LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.5718e-12-0.3626image
chr2:99195777-99196617:+LUADGSVA_HALLMARK_ADIPOGENESISEER4.3539e-02-0.0896image
chr2:99197623-99197965:+LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6106e-020.1649image
ENSG00000185414.18,MRPL30LUADGSVA_HALLMARK_ADIPOGENESISEAG3.6097e-02-0.0930image
chr2:99195777-99196617:+LUSCGSVA_HALLMARK_PROTEIN_SECRETIONEER1.1611e-02-0.1130image
chr2:99197623-99197965:+LUSCGSVA_HALLMARK_APICAL_SURFACEEER6.6964e-03-0.1761image
ENSG00000185414.18,MRPL30LUSCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.1611e-02-0.1130image
chr2:99195777-99196617:+MESOGSVA_HALLMARK_MITOTIC_SPINDLEEER3.9564e-04-0.3867image
ENSG00000185414.18,MRPL30MESOGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.9564e-04-0.3867image
ENSG00000185414.18,MRPL30OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.6397e-140.4239image
chr2:99195777-99196617:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.6360e-140.4239image
chr2:99195777-99196617:+PAADGSVA_HALLMARK_HEME_METABOLISMEER1.0215e-04-0.2879image
ENSG00000185414.18,MRPL30PAADGSVA_HALLMARK_HEME_METABOLISMEAG1.0215e-04-0.2879image
chr2:99197623-99197965:+PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER6.2086e-03-0.3412image
chr2:99195777-99196617:+PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0322e-06-0.3624image
ENSG00000185414.18,MRPL30PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0322e-06-0.3624image
chr2:99197623-99197965:+PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER4.2473e-06-0.3127image
ENSG00000185414.18,MRPL30PRADGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.8906e-06-0.2056image
chr2:99195777-99196617:+PRADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER3.8906e-06-0.2056image
ENSG00000185414.18,MRPL30READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.7163e-06-0.4601image
chr2:99195777-99196617:+READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.7163e-06-0.4601image
ENSG00000185414.18,MRPL30SARCGSVA_HALLMARK_GLYCOLYSISEAG2.3593e-030.1904image
chr2:99197623-99197965:+SARCGSVA_HALLMARK_PROTEIN_SECRETIONEER3.5611e-02-0.3252image
chr2:99195777-99196617:+SARCGSVA_HALLMARK_GLYCOLYSISEER2.3593e-030.1904image
chr2:99197623-99197965:+SKCMGSVA_HALLMARK_COAGULATIONEER3.5268e-040.2265image
ENSG00000185414.18,MRPL30SKCMGSVA_HALLMARK_HEME_METABOLISMEAG1.1011e-06-0.2235image
chr2:99195777-99196617:+SKCMGSVA_HALLMARK_HEME_METABOLISMEER1.1011e-06-0.2235image
ENSG00000185414.18,MRPL30STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.1980e-080.2754image
chr2:99195777-99196617:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.1980e-080.2754image
chr2:99195777-99196617:+TGCTGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.0473e-03-0.2650image
ENSG00000185414.18,MRPL30TGCTGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.0473e-03-0.2650image
chr2:99195777-99196617:+THCAGSVA_HALLMARK_MITOTIC_SPINDLEEER3.9276e-07-0.2250image
chr2:99197623-99197965:+THCAGSVA_HALLMARK_HYPOXIAEER3.1379e-030.2208image
ENSG00000185414.18,MRPL30THCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.9276e-07-0.2250image
chr2:99195777-99196617:+THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER8.5325e-06-0.4002image
ENSG00000185414.18,MRPL30THYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG8.5325e-06-0.4002image
chr2:99197623-99197965:+THYMGSVA_HALLMARK_HEME_METABOLISMEER3.1598e-02-0.3640image
chr2:99195777-99196617:+UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER3.0362e-05-0.3159image
ENSG00000185414.18,MRPL30UCECGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.0362e-05-0.3159image
chr2:99195777-99196617:+UCSGSVA_HALLMARK_HYPOXIAEER2.1450e-02-0.3068image
ENSG00000185414.18,MRPL30UCSGSVA_HALLMARK_HYPOXIAEAG2.1450e-02-0.3068image
ENSG00000185414.18,MRPL30UVMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.3410e-02-0.2279image
chr2:99195777-99196617:+UVMGSVA_HALLMARK_ANDROGEN_RESPONSEEER4.3410e-02-0.2279image


Top

7. Enriched editing regions and drugs for MRPL30


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr2:99195777-99196617:+ACCEmbelinEER5.8396e-040.3855image
ENSG00000185414.18,MRPL30ACCEmbelinEAG5.8396e-040.3855image
chr2:99197623-99197965:+BLCABMS.754807EER2.0192e-040.3688image
ENSG00000185414.18,MRPL30BLCAEmbelinEAG7.5736e-070.2437image
chr2:99195777-99196617:+BLCAEmbelinEER7.5736e-070.2437image
chr2:99195777-99196617:+BRCAA.770041EER1.8496e-07-0.1581image
ENSG00000185414.18,MRPL30BRCAA.770041EAG2.7095e-07-0.1559image
ENSG00000185414.18,MRPL30CESCDMOGEAG1.9957e-050.2424image
chr2:99195777-99196617:+CESCDMOGEER1.9957e-050.2424image
chr2:99197623-99197965:+CHOLLenalidomideEER9.4000e-030.5652image
ENSG00000185414.18,MRPL30CHOLJW.7.52.1EAG6.7326e-050.6216image
chr2:99195777-99196617:+CHOLJW.7.52.1EER6.7326e-050.6216image
chr2:99195777-99196617:+COADBMS.509744EER1.1118e-040.2326image
ENSG00000185414.18,MRPL30COADBMS.509744EAG1.1118e-040.2326image
ENSG00000185414.18,MRPL30DLBCAZD6482EAG3.0406e-040.5140image
chr2:99195777-99196617:+DLBCAZD6482EER3.0406e-040.5140image
ENSG00000185414.18,MRPL30ESCACGP.60474EAG1.0791e-04-0.3004image
chr2:99197623-99197965:+ESCALapatinibEER3.8522e-03-0.2402image
chr2:99195777-99196617:+ESCACGP.60474EER1.0847e-04-0.3003image
chr2:99195777-99196617:+GBMCEP.701EER2.3922e-020.1747image
ENSG00000185414.18,MRPL30GBMCEP.701EAG2.3922e-020.1747image
chr2:99197623-99197965:+GBMAG.014699EER3.5651e-020.2053image
ENSG00000185414.18,MRPL30HNSCBX.795EAG9.2320e-090.2548image
chr2:99195777-99196617:+HNSCBX.795EER9.2320e-090.2548image
chr2:99197623-99197965:+HNSCGW843682XEER6.0593e-04-0.2434image
chr2:99195777-99196617:+KICHJNK.Inhibitor.VIIIEER1.0343e-020.3160image
ENSG00000185414.18,MRPL30KICHJNK.Inhibitor.VIIIEAG1.0343e-020.3160image
chr2:99195777-99196617:+KIRCEmbelinEER5.1562e-070.2541image
ENSG00000185414.18,MRPL30KIRCEmbelinEAG5.1562e-070.2541image
chr2:99197623-99197965:+KIRCBMS.536924EER1.9700e-05-0.2696image
chr2:99197623-99197965:+KIRPAZD6482EER8.0021e-050.3639image
ENSG00000185414.18,MRPL30KIRPATRAEAG1.4286e-030.1897image
chr2:99195777-99196617:+KIRPATRAEER1.4286e-030.1897image
chr2:99195777-99196617:+LAMLA.770041EER1.7446e-02-0.1952image
ENSG00000185414.18,MRPL30LAMLA.770041EAG1.7446e-02-0.1952image
chr2:99197623-99197965:+LGGMetforminEER7.4827e-08-0.2637image
ENSG00000185414.18,MRPL30LGGBMS.708163EAG6.4484e-050.1730image
chr2:99195777-99196617:+LGGBMS.708163EER6.4484e-050.1730image
chr2:99195777-99196617:+LIHCDasatinibEER4.9498e-08-0.3041image
chr2:99197623-99197965:+LIHCBleomycinEER9.6964e-030.2372image
ENSG00000185414.18,MRPL30LIHCDasatinibEAG4.9498e-08-0.3041image
ENSG00000185414.18,MRPL30LUADLFM.A13EAG1.6150e-02-0.1067image
chr2:99195777-99196617:+LUADLFM.A13EER1.6943e-02-0.1059image
chr2:99197623-99197965:+LUADBMS.708163EER8.1283e-030.1956image
ENSG00000185414.18,MRPL30LUSCCisplatinEAG1.9998e-020.1042image
chr2:99195777-99196617:+LUSCCisplatinEER1.9998e-020.1042image
chr2:99197623-99197965:+LUSCBI.2536EER2.1874e-040.2384image
chr2:99195777-99196617:+MESOEmbelinEER1.0219e-050.4713image
ENSG00000185414.18,MRPL30MESOEmbelinEAG1.0219e-050.4713image
ENSG00000185414.18,MRPL30OVBexaroteneEAG7.9452e-100.3498image
chr2:99195777-99196617:+OVBexaroteneEER7.9411e-100.3498image
ENSG00000185414.18,MRPL30PAADCamptothecinEAG2.8590e-02-0.1670image
chr2:99195777-99196617:+PAADCamptothecinEER2.8590e-02-0.1670image
chr2:99195777-99196617:+PCPGABT.263EER1.2320e-040.2886image
chr2:99197623-99197965:+PCPGDasatinibEER6.2182e-03-0.3438image
ENSG00000185414.18,MRPL30PCPGABT.263EAG1.2320e-040.2886image
chr2:99195777-99196617:+PRADJNK.Inhibitor.VIIIEER4.1126e-060.2051image
chr2:99197623-99197965:+PRADDasatinibEER4.4042e-05-0.2799image
ENSG00000185414.18,MRPL30PRADJNK.Inhibitor.VIIIEAG4.1126e-060.2051image
ENSG00000185414.18,MRPL30READGDC0941EAG4.3628e-040.3538image
chr2:99195777-99196617:+READGDC0941EER4.3628e-040.3538image
chr2:99195777-99196617:+SARCAMG.706EER4.3866e-04-0.2194image
chr2:99197623-99197965:+SARCAMG.706EER4.5065e-02-0.3109image
ENSG00000185414.18,MRPL30SARCAMG.706EAG4.3866e-04-0.2194image
chr2:99195777-99196617:+SKCMBMS.509744EER1.1498e-04-0.1777image
ENSG00000185414.18,MRPL30SKCMBMS.509744EAG1.1498e-04-0.1777image
chr2:99197623-99197965:+SKCMGSK269962AEER6.7212e-05-0.2528image
chr2:99195777-99196617:+STADCisplatinEER7.3539e-04-0.1755image
ENSG00000185414.18,MRPL30STADCisplatinEAG7.3539e-04-0.1755image
ENSG00000185414.18,MRPL30TGCTEmbelinEAG2.5294e-030.2448image
chr2:99195777-99196617:+TGCTEmbelinEER2.5294e-030.2448image
ENSG00000185414.18,MRPL30THCAGSK269962AEAG5.4941e-08-0.2408image
chr2:99195777-99196617:+THCAGSK269962AEER5.4941e-08-0.2408image
chr2:99197623-99197965:+THCABMS.536924EER2.3016e-04-0.2735image
chr2:99197623-99197965:+THYMBMS.536924EER1.8169e-03-0.5085image
chr2:99195777-99196617:+THYMAZD6482EER6.9826e-070.4416image
ENSG00000185414.18,MRPL30THYMAZD6482EAG6.9826e-070.4416image
ENSG00000185414.18,MRPL30UCECDasatinibEAG2.2401e-07-0.3878image
chr2:99195777-99196617:+UCECDasatinibEER2.2401e-07-0.3878image
chr2:99197623-99197965:+UCECBX.795EER1.4707e-040.5025image
chr2:99195777-99196617:+UCSAxitinibEER6.2226e-03-0.3613image
ENSG00000185414.18,MRPL30UCSAxitinibEAG6.2226e-03-0.3613image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType